Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Blog Front Page BLOG POSTS IP barriers in tackling COVID 19: Anything in TRIPS to help out? Drug Exclusivities in the US: Is it justified? (Part 2 of 2) Drug Exclusivities in the US: Is it justified? (Part 1 of 2) India’s IPAB Denies Access To A Leukemia Medication In An Unsubstantiated IPAB Order And Creates Uncertainty TRIPS, COVID-19 and the Right to Repair and Produce Needed Medical Products in Emergencies (Part 2 of 2) CATEGORIES COVID-19 9 Data Exclusivities 2 Exhaustion 2 Experimental Use 1 IPAB 1 Patents 9 Trade Policy 1 TRIPS 8 TRIPS Flexibilities 1
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
